女性用性機能不全治療の世界市場2021年-2025年

◆英語タイトル:Global Female Sexual Dysfunction Treatment Market 2021-2025
◆商品コード:IRTNTR70409
◆発行会社(リサーチ会社):Technavio
◆発行日:2021年3月16日
◆ページ数:約120
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:北米、ヨーロッパ、アジア、その他
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

テクナビオ社は世界の女性用性機能不全治療市場規模が、2021年~2025年まで年平均35%成長し、276.38百万ドルに達すると予測しています。本調査レポートでは、世界の女性用性機能不全治療市場について調査・分析し、エグゼクティブサマリー、市場状況、市場規模、ファイブフォース分析、種類別(非ホルモン性治療、ホルモン性治療)分析、顧客状況、地域別状況、企業状況、企業分析などをまとめております。
・エグゼクティブサマリー
・市場状況
・市場規模
・ファイブフォース分析
・世界の女性用性機能不全治療市場規模:種類別(非ホルモン性治療、ホルモン性治療)
・顧客状況
・地域別状況
・企業状況
・企業分析
【レポートの概要】

Global Female Sexual Dysfunction Treatment Market 2021-2025
Technavio has been monitoring the female sexual dysfunction treatment market and it is poised to grow by $ 276.38 mn during 2021-2025, progressing at a CAGR of about 35% during the forecast period. Our report on female sexual dysfunction treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increasing prevalence of chronic diseases and growing awareness of female sexual dysfunction. In addition, increasing prevalence of chronic diseases is anticipated to boost the growth of the market as well.
The female sexual dysfunction treatment market analysis includes type segment and geographical landscapes.

Technavio’s female sexual dysfunction treatment market is segmented as below:
By Type
• Non-hormonal therapy
• Hormonal therapy

By Geographical Landscapes
• North America
• Europe
• Asia
• ROW

This study identifies approval and availability of drug to treat hypoactive sexual desire disorder as one of the prime reasons driving the female sexual dysfunction treatment market growth during the next few years.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on female sexual dysfunction treatment market covers the following areas:
• Female sexual dysfunction treatment market sizing
• Female sexual dysfunction treatment market forecast
• Female sexual dysfunction treatment market industry analysis

Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading female sexual dysfunction treatment market vendors that include Cipla Inc., Duchesnay Inc., Emotional Brain BV, Mithra Pharmaceuticals SA, Mylan NV, Novo Nordisk AS, Palatin Technologies Inc., Pfizer Inc., Sprout Pharmaceuticals Inc., and Strategic Science and Technologies LLC. Also, the female sexual dysfunction treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors. For further information on this report, please visit – https://www.technavio.com/report/female-sexual-dysfunction-treatment-market-industry-analysis
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research – both primary and secondary. Technavio’s market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

【レポートの目次】

• Executive Summary
o Market Overview
• Market Landscape
o Market ecosystem
o Value chain analysis
• Market Sizing
o Market definition
o Market segment analysis
o Market size 2020
o Market outlook: Forecast for 2020 – 2025
• Five Forces Analysis
o Five forces summary
o Bargaining power of buyers
o Bargaining power of suppliers
o Threat of new entrants
o Threat of substitutes
o Threat of rivalry
o Market condition
• Market Segmentation by Type
o Market segments
o Comparison by Type
o Non-hormonal therapy – Market size and forecast 2020-2025
o Hormonal therapy – Market size and forecast 2020-2025
o Market opportunity by Type
• Customer landscape
o Customer landscape
• Geographic Landscape
o Geographic segmentation
o Geographic comparison
o North America – Market size and forecast 2020-2025
o Europe – Market size and forecast 2020-2025
o Asia – Market size and forecast 2020-2025
o ROW – Market size and forecast 2020-2025
o Key leading countries
o Market opportunity by geography
o Market drivers
o Market challenges
o Market trends
• Vendor Landscape
o Competitive scenario
o Vendor landscape
o Landscape disruption
o Industry risks
• Vendor Analysis
o Vendors covered
o Market positioning of vendors
o Cipla Inc.
o Duchesnay Inc.
o Emotional Brain BV
o Mithra Pharmaceuticals SA
o Mylan NV
o Novo Nordisk AS
o Palatin Technologies Inc.
o Pfizer Inc.
o Sprout Pharmaceuticals Inc.
o Strategic Science and Technologies LLC
• Appendix
o Scope of the report
o Currency conversion rates for US$
o Research methodology
o List of abbreviations

Exhibit
• 1: Key Finding 1
• 2: Key Finding 2
• 3: Key Finding 3
• 4: Key Finding 5
• 5: Key Finding 6
• 6: Key Finding 7
• 7: Key Finding 8
• 8: Parent market
• 9: Market characteristics
• 10: Offerings of vendors included in the market definition
• 11: Market segments
• 12: Global – Market size and forecast 2020 – 2025 ($ million)
• 13: Global market: Year-over-year growth 2020 – 2025 (%)
• 14: Five forces analysis 2020 & 2025
• 15: Bargaining power of buyers
• 16: Bargaining power of suppliers
• 17: Threat of new entrants
• 18: Threat of substitutes
• 19: Threat of rivalry
• 20: Market condition – Five forces 2020
• 21: Type – Market share 2020-2025 (%)
• 22: Comparison by Type
• 23: Non-hormonal therapy – Market size and forecast 2020-2025 ($ million)
• 24: Non-hormonal therapy – Year-over-year growth 2020-2025 (%)
• 25: Hormonal therapy – Market size and forecast 2020-2025 ($ million)
• 26: Hormonal therapy – Year-over-year growth 2020-2025 (%)
• 27: Market opportunity by Type
• 28: Customer landscape
• 29: Market share by geography 2020-2025 (%)
• 30: Geographic comparison
• 31: North America – Market size and forecast 2020-2025 ($ million)
• 32: North America – Year-over-year growth 2020-2025 (%)
• 33: Europe – Market size and forecast 2020-2025 ($ million)
• 34: Europe – Year-over-year growth 2020-2025 (%)
• 35: Asia – Market size and forecast 2020-2025 ($ million)
• 36: Asia – Year-over-year growth 2020-2025 (%)
• 37: ROW – Market size and forecast 2020-2025 ($ million)
• 38: ROW – Year-over-year growth 2020-2025 (%)
• 39: Key leading countries
• 40: Market opportunity by geography ($ million)
• 41: Impact of drivers and challenges
• 42: Vendor landscape
• 43: Landscape disruption
• 44: Industry risks
• 45: Vendors covered
• 46: Market positioning of vendors
• 47: Cipla Inc. – Overview
• 48: Cipla Inc. – Business segments
• 49: Cipla Inc. – Key offerings
• 50: Cipla Inc. – Key customers
• 51: Cipla Inc. – Segment focus
• 52: Duchesnay Inc. – Overview
• 53: Duchesnay Inc. – Product and service
• 54: Duchesnay Inc. – Key offerings
• 55: Duchesnay Inc. – Key customers
• 56: Duchesnay Inc. – Segment focus
• 57: Emotional Brain BV – Overview
• 58: Emotional Brain BV – Product and service
• 59: Emotional Brain BV – Key offerings
• 60: Emotional Brain BV – Key customers
• 61: Emotional Brain BV – Segment focus
• 62: Mithra Pharmaceuticals SA – Overview
• 63: Mithra Pharmaceuticals SA – Product and service
• 64: Mithra Pharmaceuticals SA – Key offerings
• 65: Mithra Pharmaceuticals SA – Key customers
• 66: Mithra Pharmaceuticals SA – Segment focus
• 67: Mylan NV – Overview
• 68: Mylan NV – Business segments
• 69: Mylan NV – Key offerings
• 70: Mylan NV – Key customers
• 71: Mylan NV – Segment focus
• 72: Novo Nordisk AS – Overview
• 73: Novo Nordisk AS – Product and service
• 74: Novo Nordisk AS – Key offerings
• 75: Novo Nordisk AS – Key customers
• 76: Novo Nordisk AS – Segment focus
• 77: Palatin Technologies Inc. – Overview
• 78: Palatin Technologies Inc. – Product and service
• 79: Palatin Technologies Inc. – Key offerings
• 80: Palatin Technologies Inc. – Key customers
• 81: Palatin Technologies Inc. – Segment focus
• 82: Pfizer Inc. – Overview
• 83: Pfizer Inc. – Business segments
• 84: Pfizer Inc. – Key offerings
• 85: Pfizer Inc. – Key customers
• 86: Pfizer Inc. – Segment focus
• 87: Sprout Pharmaceuticals Inc. – Overview
• 88: Sprout Pharmaceuticals Inc. – Product and service
• 89: Sprout Pharmaceuticals Inc. – Key offerings
• 90: Sprout Pharmaceuticals Inc. – Key customers
• 91: Sprout Pharmaceuticals Inc. – Segment focus
• 92: Strategic Science and Technologies LLC – Overview
• 93: Strategic Science and Technologies LLC – Product and service
• 94: Strategic Science and Technologies LLC – Key offerings
• 95: Strategic Science and Technologies LLC – Key customers
• 96: Strategic Science and Technologies LLC – Segment focus
• 97: Currency conversion rates for US$
• 98: Research Methodology
• 99: Validation techniques employed for market sizing
• 100: Information sources
• 101: List of abbreviations



【掲載企業】

Cipla Inc., Duchesnay Inc., Emotional Brain BV, Mithra Pharmaceuticals SA, Mylan NV, Novo Nordisk AS, Palatin Technologies Inc., Pfizer Inc., Sprout Pharmaceuticals Inc., Strategic Science and Technologies LLC

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[女性用性機能不全治療の世界市場2021年-2025年]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆